Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

689 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized Phase 3 trial demonstrating high efficacy, favourable safety and convenience of a novel calcipotriol and betamethasone dipropionate cream for the treatment of psoriasis.
Pinter A, Reich A, Arenberger P, Gold LS, Armstrong A, Iversen L, Praestegaard M, Augustin M. Pinter A, et al. J Eur Acad Dermatol Venereol. 2023 Nov;37(11):2327-2335. doi: 10.1111/jdv.19330. Epub 2023 Aug 25. J Eur Acad Dermatol Venereol. 2023. PMID: 37432045 Clinical Trial.
A phase 4, randomized, head-to-head trial comparing the efficacy of subcutaneous injections of brodalumab to oral administrations of fumaric acid esters in adults with moderate-to-severe plaque psoriasis (CHANGE).
Pinter A, Hoffmann M, Reich K, Augustin M, Kaplan K, Gudjónsdóttir SD, Delvin T, Mrowietz U; CHANGE investigator group. Pinter A, et al. J Eur Acad Dermatol Venereol. 2021 Mar;35(3):701-711. doi: 10.1111/jdv.16932. Epub 2020 Dec 23. J Eur Acad Dermatol Venereol. 2021. PMID: 32939860 Clinical Trial.
Efficacy and safety of ixekizumab after switching from fumaric acid esters or methotrexate in patients with moderate-to-severe plaque psoriasis naïve to systemic treatment.
Leutz A, Pinter A, Thaçi D, Augustin M, Schuster C, Fotiou K, Hundemer HP, Saure D, Mrowietz U, Reich K. Leutz A, et al. Among authors: pinter a. Br J Dermatol. 2021 Mar;184(3):548-550. doi: 10.1111/bjd.19558. Epub 2020 Nov 10. Br J Dermatol. 2021. PMID: 32940343 No abstract available.
Patient-reported outcomes with risankizumab versus fumaric acid esters in systemic therapy-naïve patients with moderate to severe plaque psoriasis: a phase 3 clinical trial.
Thaçi D, Soliman AM, Eyerich K, Pinter A, Sebastian M, Unnebrink K, Rubant S, Williams DA, Weisenseel P. Thaçi D, et al. Among authors: pinter a. J Eur Acad Dermatol Venereol. 2021 Aug;35(8):1686-1691. doi: 10.1111/jdv.17109. Epub 2021 Jul 12. J Eur Acad Dermatol Venereol. 2021. PMID: 33428281 Clinical Trial.
Nemolizumab is associated with a rapid improvement in atopic dermatitis signs and symptoms: subpopulation (EASI ≥ 16) analysis of randomized phase 2B study.
Silverberg JI, Pinter A, Alavi A, Lynde C, Bouaziz JD, Wollenberg A, Murrell DF, Alpizar S, Laquer V, Chaouche K, Ahmad F, Armstrong JM, Piketty C. Silverberg JI, et al. Among authors: pinter a. J Eur Acad Dermatol Venereol. 2021 Jul;35(7):1562-1568. doi: 10.1111/jdv.17218. Epub 2021 Apr 1. J Eur Acad Dermatol Venereol. 2021. PMID: 33711179 Clinical Trial.
A pooled analysis of randomized, controlled, phase 3 trials investigating the efficacy and safety of a novel, fixed dose calcipotriene and betamethasone dipropionate cream for the topical treatment of plaque psoriasis.
Pinter A, Green LJ, Selmer J, Praestegaard M, Gold LS, Augustin M; trial investigator group. Pinter A, et al. J Eur Acad Dermatol Venereol. 2022 Feb;36(2):228-236. doi: 10.1111/jdv.17734. Epub 2021 Nov 5. J Eur Acad Dermatol Venereol. 2022. PMID: 34628687
Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial.
Augustin M, Reich K, Yamauchi P, Pinter A, Bagel J, Dahale S, You R, Bruin G, Djimopoulos J, Paguet B, Charef P, Patekar M, Keefe D. Augustin M, et al. Among authors: pinter a. Br J Dermatol. 2022 Jun;186(6):942-954. doi: 10.1111/bjd.20971. Epub 2022 Apr 8. Br J Dermatol. 2022. PMID: 34981829 Clinical Trial.
Long-term, durable, absolute Psoriasis Area and Severity Index and health-related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate-to-severe plaque psoriasis.
Gooderham M, Pinter A, Ferris LK, Warren RB, Zhan T, Zeng J, Soliman AM, Kaufmann C, Kaplan B, Photowala H, Strober B. Gooderham M, et al. Among authors: pinter a. J Eur Acad Dermatol Venereol. 2022 Jun;36(6):855-865. doi: 10.1111/jdv.18010. Epub 2022 Mar 17. J Eur Acad Dermatol Venereol. 2022. PMID: 35174556 Free PMC article. Clinical Trial.
Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical Trial.
Paller AS, Seyger MMB, Magariños GA, Pinter A, Cather JC, Rodriguez-Capriles C, Zhu D, Somani N, Garrelts A, Papp KA; IXORA-PEDS Investigators. Paller AS, et al. Among authors: pinter a. JAMA Dermatol. 2022 May 1;158(5):533-541. doi: 10.1001/jamadermatol.2022.0655. JAMA Dermatol. 2022. PMID: 35416908 Free PMC article. Clinical Trial.
689 results